News

CVS Caremark drops coverage of popular weight loss drug
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
CVS Caremark drops GLP-1 weight loss drug, Zepbound
CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.
pharmaphorum4h
Novo Nordisk files high-dose Wegovy in EU
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
WeightWatchers back from the brink as company brands fad diets and fat jabs like Ozempic and Mounjaro a 'quick fix'
The dramatic rise of weight-loss drugs such as Ozempic and Mounjaro had upended WeightWatchers' business model ...
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
IDA Ireland4h
Key players in Ireland’s pharmaceutical manufacturing space
Ireland has long been a global pharmaceutical powerhouse, hosting more than 90 pharmaceutical companies and employing around ...
MetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...